Businesswire·2025-11-03 12:57Core Viewpoint - Pfizer has filed a second lawsuit against Metsera, its controlling stockholders, and Novo Nordisk, claiming that Novo Nordisk's proposal to acquire Metsera is anticompetitive and violates antitrust laws [1][2][4]. Summary by Sections Lawsuit Details - The lawsuit alleges that Novo Nordisk's acquisition proposal aims to eliminate a potential competitor in the GLP-1 drug market, which could harm millions of Americans suffering from obesity and diabetes [2]. - Pfizer claims that the proposed transaction violates Section 7 of the Clayton Act and constitutes an anticompetitive conspiracy under the Sherman Act [2]. Legal Actions - Pfizer seeks injunctive relief to prevent Novo Nordisk's proposed transaction from proceeding [3]. - The company has also filed a separate lawsuit in the Delaware Court of Chancery against Metsera and its Board of Directors for breach of contract and fiduciary duty related to the merger agreement [4][11]. Company Statements - Pfizer emphasizes that the lawsuit is intended to preserve competition in the therapeutic area and to prevent Novo Nordisk from undermining an emerging competitor [4]. - The company expresses confidence in the merits of its case and looks forward to presenting it in court [4].